136 related articles for article (PubMed ID: 36891289)
1. Regional and age-dependent changes in ubiquitination in cellular and mouse models of Spinocerebellar ataxia type 3.
Luo H; Todi SV; Paulson HL; Costa MDC
bioRxiv; 2023 Feb; ():. PubMed ID: 36891289
[TBL] [Abstract][Full Text] [Related]
2. Regional and age-dependent changes in ubiquitination in cellular and mouse models of spinocerebellar ataxia type 3.
Luo H; Todi SV; Paulson HL; Costa MDC
Front Mol Neurosci; 2023; 16():1154203. PubMed ID: 37122622
[TBL] [Abstract][Full Text] [Related]
3. Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model.
Jansen-West K; Todd TW; Daughrity LM; Yue M; Tong J; Carlomagno Y; Del Rosso G; Kurti A; Jones CY; Dunmore JA; Castanedes-Casey M; Dickson DW; Wszolek ZK; Fryer JD; Petrucelli L; Prudencio M
Front Cell Dev Biol; 2022; 10():863089. PubMed ID: 35386195
[TBL] [Abstract][Full Text] [Related]
4. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
5. Loss of the Spinocerebellar Ataxia type 3 disease protein ATXN3 alters transcription of multiple signal transduction pathways.
Zeng L; Zhang D; McLoughlin HS; Zalon AJ; Aravind L; Paulson HL
PLoS One; 2018; 13(9):e0204438. PubMed ID: 30231063
[TBL] [Abstract][Full Text] [Related]
6. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
7. Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV
J Neurol Sci; 2023 Nov; 454():120828. PubMed ID: 37865002
[TBL] [Abstract][Full Text] [Related]
8. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
9. Lysine 117 on ataxin-3 modulates toxicity in
Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV
bioRxiv; 2023 Jun; ():. PubMed ID: 37398109
[TBL] [Abstract][Full Text] [Related]
10. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3.
Koike Y; Jansen-West KR; Hanna Al-Shaikh R; Carlomagno Y; Song Y; Dunmore JA; LeDoux MS; Friedman JH; Pena AB; Uitti RJ; Zaremba J; van Gerpen JA; Pfeiffer RF; Veerappan V; Aiba I; Hashimoto R; Giles SS; Shah JS; Tipton PW; Huang JF; Wierenga KJ; Aasly J; Fryer JD; Petrucelli L; Wszolek ZK; Prudencio M
Parkinsonism Relat Disord; 2021 Aug; 89():151-154. PubMed ID: 34303201
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin-binding site 1 of pathogenic ataxin-3 regulates its toxicity in
Prifti MV; Libohova K; Harris AL; Tsou WL; Todi SV
Front Neurosci; 2022; 16():1112688. PubMed ID: 36733922
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
[TBL] [Abstract][Full Text] [Related]
13. The Josephin domain (JD) containing proteins are predicted to bind to the same interactors: Implications for spinocerebellar ataxia type 3 (SCA3) studies using
Sousa E Silva R; Sousa AD; Vieira J; Vieira CP
Front Mol Neurosci; 2023; 16():1140719. PubMed ID: 37008788
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.
Moore LR; Rajpal G; Dillingham IT; Qutob M; Blumenstein KG; Gattis D; Hung G; Kordasiewicz HB; Paulson HL; McLoughlin HS
Mol Ther Nucleic Acids; 2017 Jun; 7():200-210. PubMed ID: 28624196
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
16. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
[TBL] [Abstract][Full Text] [Related]
17. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
[TBL] [Abstract][Full Text] [Related]
18. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL
Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
Krauss S; Nalavade R; Weber S; Carter K; Evert BO
Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
[TBL] [Abstract][Full Text] [Related]
20. Altered retinal structure and function in Spinocerebellar ataxia type 3.
Toulis V; Casaroli-Marano R; Camós-Carreras A; Figueras-Roca M; Sánchez-Dalmau B; Muñoz E; Ashraf NS; Ferreira AF; Khan N; Marfany G; Costa MDC
Neurobiol Dis; 2022 Aug; 170():105774. PubMed ID: 35605759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
